. 2011 Jun 10;6(6):e20501. doi: 10.1371/journal.pone.0020501

Table 2. PADK selectively enhances cathepsin B levels in two transgenic mouse models.

	APP_SwInd+veh	APP_SwInd+PADK	APP−PS1+veh	APP−PS1+PADK
CB	95.3±14.2	404.6±36.0^***	44.5±15.2	376.0±38.6^***
nep	89.1±19.2	95.3±16.6	43.0±6.5	31.5±6.6
IDE	101.1±11.0	76.4±6.5	96.1±8.3	89.5±6.0
α-sec	82.3±6.0	92.0±5.2	60.1±8.9	58.9±6.2
LAMP1	98.4±5.4	102.2±8.6	46.1±9.9	45.8±4.6

APP_SwInd and APP-PS1 mice were injected i.p. daily with PADK (20 mg/kg; n = 11−13) or vehicle (n = 10) for 9–11 days. Hippocampal homogenates were analyzed by immunoblot and mean immunoreactivities are shown for active cathepsin B (CB), neprilysin (nep), insulin-degrading enzyme (IDE), α-secretase (α-sec), and LAMP1.

***P<0.0001, unpaired t-test.